Análisis Argos
IDXX
IDXXCara
IDEXX Laboratories, Inc. · Healthcare
US$ 557.80
precio al 2026-07-04
Valor justo Argos*
US$ 199–254
vs. su valor justo
148% por encima
Score Argos
51/100
LA RESPUESTA
El mercado le pide crezca 33.4% al año — más de lo que ha demostrado (13.2%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Las ganancias crecieron 19% el último año.
✓Retorno sobre el capital alto (44%).
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR1/6FUTURO4/6PASADO6/6SALUD6/6DIVIDENDO3/6
El Iris de calidad
VALOR1/6FUTURO4/6PASADO6/6SALUD6/6DIVIDENDO3/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoRetorno al accionista moderado
Score Argos51de 100Cara
Ingresos▲10%
US$ 4.3 B
Margen operativo▲9%
31.6%
Flujo de caja libre▲31%
US$ 1.1 B
Deuda neta
US$ 0.9 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 44.0B
P/E41.5x
EV/EBITDA30.6x
FCF yield2.4%
ROIC43.5%
Margen operativo31.6%
Crecim. ingresos+10.4%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

businesswire.com · 1 jul
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2026 Earnings Snapshot through a link on the IDEXX websi.
zacks.com · 30 jun
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com · 29 jun
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock?
Investors need to pay close attention to IDXX stock based on the movements in the options market lately.
gurufocus.com · 17 jun
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 96/100
On June 17, 2026, IDEXX Laboratories Inc (IDXX) shares fell 4.7% to $546.09. The stock's current price is within a 52-week range of $506.91 to $769.98, reflecti
zacks.com · 11 jun
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com · 9 jun
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com · 4 jun
Idexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
marketbeat.com · 30 may
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
IDEXX Laboratories NASDAQ: IDXX President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company's innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.